If not before, then certainly since the first messenger RNA (mRNA) vaccines to combat the SARS-CoV2 virus were approved in Germany, mRNA has become a recognized term even outside scientific circles. What is less well known is that mRNA can be used to produce much more than just vaccines. Around 50 different procedures for the treatment of diseases including cancer are already being studied in clinical trials. Scientists from the pharmaceutical company AstraZeneca, with the support of neutron researchers from Forschungszentrum Jülich, have now discovered how the subcutaneous administration of mRNA can be improved. The goal is for chronically ill patients to be able to self-administer the medication on a regular basis.